Abstract
Background: Preeclampsia (PE) affects approximately 3% of all pregnancies, and it is still a major cause of the adverse perinatal outcome. PE is a multisystem disease characterized by the development of hypertension and proteinuria. Although PE etiology is not fully known, the placenta seems to play a central role in the development of the disease. The inadequate placentation process results in a change in angiogenic factors levels, such as the soluble form of vascular endothelial growth factor receptor type 1 (sFlt-1) and placental growth factor (PLGF). Objectives: To investigate the correlation between serum PLGF with soluble sFLT-1 in preeclamptic women at their third trimester. Methods: A case-control study was carried out from August 2018 till January 2019. In this study, pregnant women were collected from the Al-Elweyia, Al-Hakeem, and Al-Imamain Alkadhimain medical city. The practical part was conducted at the College of Medicine, Al-Nahrain University. The patient group includes 50 preeclamptic women in the third trimester (25 mild and 25 severe). Fifty healthy pregnant women (at their third trimester of gestation) were selected as control. Patients and control were compared for age, serum PLGF, and Sflt-1. Results: Serum PLGF levels were decreased significantly among women who developed PE (2.14±0.029 pg/ml, 2.44±0.038 pg/ml vs. 2.68±0.017 pg/ml; p<0.05) severe PE, Mild PE, and the control group respectively, while, serum sFlt1 levels were increased significantly (p<0.05) between the groups of PE, (5.81±0.025, 5.51±0.024, 5.19±0.017 pg/ml) severe, mild and control, respectively. Conclusions: Serum sFlt-1 and PLGF can be considered promising biomarkers for the preeclampsia. sFlt-1 and PLGF the ROC cut-offs (5.67 ng/ml, 2.09 ng/ml, respectively), the specificity and sensitivity of serum PLGF is more than that of serum sFlt-1, for the diagnosis of preeclampsia during the third trimester of pregnancy.
Highlights
Preeclampsia (PE), which affects 2–3% of pregnancies and is a major cause of maternal and perinatal morbidity and mortality, is thought to be the consequence of an imbalance in angiogenic and anti-angiogenic proteins
Preeclampsia is associated with an altered maternal pattern of circulating placentally derived proteins regulating angiogenesis such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PLGF).[2]
The present study showed increases in the levels of serum soluble fms-like tyrosine kinase-1 in preeclampsia compared with the pregnant control group in the third trimester
Summary
Preeclampsia (PE), which affects 2–3% of pregnancies and is a major cause of maternal and perinatal morbidity and mortality, is thought to be the consequence of an imbalance in angiogenic and anti-angiogenic proteins. Several studies have reported that maternal serum levels of placental growth factor (PLGF) are reduced and those of soluble fms-like tyrosine kinase-1 (sFlt-1) are increased in women with PE. There is evidence that the level of these proteins is altered before the onset of the clinical signs of the disease. Preeclampsia is associated with an altered maternal pattern of circulating placentally derived proteins regulating angiogenesis such as sFlt-1 (soluble fms-like tyrosine kinase 1) and PLGF (placental growth factor).[2]. The inadequate placentation process results in a change in angiogenic factors levels, such as the soluble form of vascular endothelial growth. Methods: A case-control study was carried out from August 2018 till January 2019
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
